In 2012, Hambruch et al. investigated the effects of synthetic FXR agonists on cholesterol metabolism and atherosclerosis prevention,[101] demonstrating that different FXR agonists are able to induce variations in pharmacological effects on liver gene expression and the clearance of HDL‐derived cholesterol into feces. The gene discussed is NR1H4; the disease is atherosclerosis.